Biogen on hold by Jefferies

Biogen Idec Inc. was maintained at hold by Jefferies & Co., Inc. analyst Adam Walsh ahead of expected Tysabri re-approval. The company reported first-quarter 2006 earnings per share $0.07 ahead of Jefferies' estimate and Street consensus. Shares of the Cambridge, Mass., pharmaceutical company were down 11 cents, or 0.24%, at $44.85 on volume of 3,103,772 shares versus the three-month running average of 3,594,390 shares. (Nasdaq: BIIB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.